Effect of a Non-polymer Titanium Dioxide Thin Film-Coated Stent with Heparin in a Porcine Coronary Restenosis Model

Kyung Seob Lim,1,2,3 Myung Ho Jeong,1,2,3,4 In Ho Bae,1,2 Jun-Kyu Park,2,3 Dae Sung Park,2,3 Jae Won Shim,2,3 Han Byual Kim,2,3 Mi Rim Jin,2,3 Hyun Kuk Kim,6 Sung Soo Kim,6 Min Chul Kim,2,3 Doo Sun Sim,2,3 Young Joon Hong,2,3 Ju Han Kim,2,3 Youngkeun Ahn2,3

1Korea Cardiovascular Stent Institute, Janggun, Korea
2Cardiovascular Convergence Research Center, Nominated by the Korea Ministry of Health and Welfare, Gwangju, Korea
3Cardiovascular Research Center, Chonnam National University, Gwangju, Korea
4Regeneromics Research Center, Chonnam National University, Gwangju, Korea
5CGBio Co. Ltd, Jangseong-gun, Korea
6Division of Cardiology, Chosun University Hospital, Gwangju, Korea

Received: 1 September 2017 Accepted: 13 November 2017

*Corresponding author:
Myung Ho Jeong, MD, PhD, FACC, FASE, FESC, FSCAI
Director of Korea Cardiovascular Stent Research Institute, Director of Cardiovascular Convergence Research Center Nominated by Korea Ministry of Health and Welfare, 671 Jaejong-ro, Dong-gu, Gwangju 61489, Korea
Tel: +82-62-228-6249 Fax: +82-62-228-7174
E-mail: myungho@chollian.net, mhjeong@chonnam.ac.kr

Purpose: The aim of this study was to examine the effect of non-polymer titanium dioxide (TiO2) thin film-coated stents modified with heparin in a porcine coronary overstretch restenosis model.

Methods: Pigs were randomized into three groups in which either TiO2 film-heparin coated stent (THS, n = 12), zotarolimus-eluting stent with polymer (ZES, n = 12), or bare metal stent (BMS, n = 12) was placed in a coronary artery (18 pigs, 12 coronaries in each group). Histopathologic analysis was performed at 28 days after stenting.

Results: There was no significant difference in injury score among the three groups. There were significant differences in neointima area (2.9 ± 0.85 mm2 in the THS group vs. 2.8 ± 0.10 mm2 in the ZES group vs. 3.3 ± 0.58 mm2 in the BMS group, P < 0.05), fibrin score (0.0 [range 0.0 to 1.0] in the THS group vs. 2.0 [range 2.0 to 2.0] in the ZES group vs. 0.5 [range 0.0 to 2.0] in the BMS group, P < 0.0001), and inflammation score (1.0 [range 0.0-1.0] in the THS group vs. 1.0 [range 1.0 to 2.0] in the ZES group vs. 0.5 [range 0.75 to 1.0] in the BMS group, P < 0.0001) among the three groups. In-stent restenosis rate, as measured by micro-computed tomography, demonstrated similar percent area values upon histology analysis (57.7 ± 13.14% in the THS group vs. 58.7 ± 16.44% in the ZES group vs. 64.8 ± 8.56% in the BMS group, P < 0.05).

Conclusion: THS is more effective in reducing neointima formation compared to BMS. Moreover, the neo-intima suppressive effect of THS exceeds that of commercial ZES, with lower fibrin and inflammation scores in a porcine coronary restenosis model.

Keywords: Stents, Percutaneous coronary intervention, Restenosis, Inflammation

Introduction

First-generation drug-eluting stents (DES) have successfully solved the problems related to the high restenosis rate of bare metal stents (BMS). However, those improvements were accompanied by an increased risk of delayed re-endothelialization and stent thrombosis (ST).1,2 The shortcomings of ST and poor re-endothelialization might be related to the polymers used for drug coating on BMS.3-5 To address this problem, a more biocompatible polymer and thin stent strut of cobalt-chromium alloy were applied in next-generation DES.6 Therefore, the ST of second-generation DES was significantly lower than that of first-generation DES.7 However, the remaining polymer after drug release might still have potential risk for occurrences such as polymer-induced inflammation.

So, we developed a polymer-free drug-combining technology to reduce the side effects of polymer-based DES. Titanium has been used for improving the blood compatibility of medical devices, such as coronary stents, artificial valves, and ventricular assist devices (VAD).

Heparin offers an antiocoagulation effect and inhibits vascular smooth muscle cell (VSMC) proliferation.8-12 The aim of the present study was to evaluate the effect of the non-polymer titanium dioxide (TiO2) thin film-coated stent with heparin in a porcine coronary overstretch restenosis model.

Methods

Materials
Porcine intestinal-mucosal sodium salt heparin (grade 1-A; 181 usp units/mg) was used in this study. Heparin sodium salt was purchased from Sigma-Aldrich Co. (USA). All other reagents were of analytical grade.

Preparation of TiO2 film-heparin coated stent
A TiO2 thin film was deposited onto a bare metal stent (3.0 mm × 16 mm, cobalt-chromium alloy) by a plasma-enhanced chemical vapor deposition (PECVD) process, and its potential as a drug-combining matrix was investigated. When deposited at a discharge power of 5 W, the film showed a highly smooth surface with a roughness of 9.4 nm, adequate mechanical stability with good adhesion, and good blood compatibility. The film was surface-modified with water plasma to introduce hydroxyl groups on the TiO2 surface. Then, drugs...
could be chemically grafted onto the modified surface through the formation of ester bonds between hydroxyl groups on the modified TiO$_2$ film and carboxyl groups in the heparin. When heparin was grafted onto the TiO$_2$-deposited and surface-modified stents, the grafted amount was measured to be 53.9 μg on average. In the in vitro drug-release test, heparin was released continuously for four weeks.  

**Animal preparation and stent implantation**

The animal study was approved by the Ethics Committee of Chonnam National University Medical School and Chonnam National University Hospital (CNU IAEC-H-2012-24) and conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). Study animals were castrated male pigs weighing 20-25 kg. To prevent acute thrombosis after stenting, daily pre-medication with aspirin (100 mg) and clopidogrel (75 mg) was administered for five days before the procedure. On the procedure day, pigs were anesthetized with zolazepam and tiletamine (2.5 mg/kg, Zoletil 50®, Virbac, Caros, France), xylazine (3 mg/kg, Rompun®, Bayer AG, Leverkusen, Germany), and azaperone (6 mg/kg, Stresnil®, Janssen-Cilag, Neuss, Germany). The pigs received continuous supplemental oxygen through an oxygen mask. Subcutaneous 2% lidocaine at the cut-down site was administered, the left carotid artery was surgically exposed, and a 7-French sheath was inserted.

Continuous hemodynamic and surface electrocardiographic monitoring was maintained throughout the procedure. Then, 5,000 units of heparin were administered intravenously as a bolus prior to the procedure, the target coronary artery was engaged using standard 7-F guide catheters, and control angiograms of both coronary arteries were performed using a non-ionic contrast agent in two orthogonal views.

The stent was deployed by inflating the balloon to a stent-to-artery ratio of 1.3:1. Coronary angiograms were obtained immediately after stent implantation. Then, all equipment was removed, and the carotid artery was ligated.

Four weeks after stenting, the animals underwent follow-up angiography using the same orthogonal views before death via 20 mL of potassium chloride intracoronary injection.

The hearts were removed, and the coronary arteries were pressure-perfusion fixed at 110 mmHg in 10% neutral buffered formalin overnight. Each of 10 stented arteries was step-sectioned, processed routinely for light microscopy, and stained for histological analysis. All specimens were evaluated by micro-computerized tomography (M-CT). Two specimens each from the three groups was analyzed by scanning electron microscopy (SEM).

---

**Fig. 1.** The Carstair fibrin stain of the low- and high-power fields (magnitudes, 20×, 200×) showing fibrin infiltration in THS implant (A, A-1), ZES implant (B, B-1), and BMS implant (C, C-1) cases. Black arrow indicates fibrin deposition. THS, TiO$_2$ film-heparin coated stent; ZES, zotarolimus-eluting stent with biocompatible polymer; BMS, bare metal stent.
Study groups
The pigs were randomly divided into three groups: group 1 (TiO$_2$ film-heparin coated stent, THS, 3.0 mm × 16 mm, n = 12), group 2 (zotarolimus-eluting stent with biocompatible polymer, ZES, Endeavor Resolute®, Medtronic CardioVascular, Minneapolis, MN, USA, 3.0 mm × 16 mm, n = 12), and group 3 (BMS, 3.0 mm × 16 mm, n = 12).

A total of 18 pigs were used in this study (18 pigs, 36 coronary arteries, 12 coronary arteries in each group). A THS, a ZES, and a BMS were implanted in the left anterior descending artery and left circumflex artery in a randomized manner.

Histopathologic, scanning electron microscopy, and micro-computed tomography analysis
Histopathologic evaluation of each artery was performed by an experienced cardiovascular pathologist. The specimens were embedded, and sections of 3-4 µm thickness were obtained at approximately 1 mm intervals. Sections were then stained with hematoxylin-eosin and Carstairs’ for histological analysis. Measurements of the histopathologic sections were performed using a calibrated microscope, digital video imaging system, and microcomputer program (Visus 2000 Visual Image Analysis System, IMT Tech, CA, USA). Borders were manually traced for lumen area, area circumscribed by the internal elastic lamina, and the innermost border of the external elastic lamina (external elastic lamina area). Morphometric analysis of the neointimal area for a given vessel was calculated as the measured internal elastic lamina area minus the lumen area. The measurements were performed on five cross-sections from the proximal and distal ends and three midpoints of each stented segment. Histopathologic stenosis was calculated as 100 × (1-[lesion lumen area/lesion internal elastic lamina area]). The harvested stent specimen was stored in formaldehyde solution. A 1.5-mL Eppendorf tube was filled with clay to form it into a V shape to hold the stent during contrast agent staining. The stents were removed from the solution and placed vertically in the V-shaped opening in the clay. Each stent had to be fixed with clay such that there was no movement of the stent inside the Eppendorf tube. The contrast agent used was omnihexol. One milliliter of contrast agent was placed in a 5-mL syringe and injected through the opening at the center of the stent. The stent was incubated with contrast agent overnight and subjected to M-CT imaging. After performing M-CT analysis, the longitudinally cut sections were rinsed three times using sodium phosphate, fixed in 1% osmium tetroxide, and then rinsed in distilled water. The specimens were dehydrated in a graded series of alcohols, critically point dried, placed in a vacuum coater, and coated with 30-40 nm gold. Luminal surfaces were SEM photographed at 100 × .

Fig. 2. Representative images of hematoxylin and eosin staining at four weeks after stenting. Specimen THS implanted (A: 20 ×, A-1: 200 ×), ZES implanted (B: 20 ×, B-1: 200 ×), and BMS implanted (C: 20 ×, C-1: 200 ×).

THS, TiO$_2$ film-heparin coated stent; ZES, zotarolimus-eluting stent with biocompatible polymer; BMS, bare metal stent.
Evaluation of arterial injury
Arterial injury at each strut site was determined by the anatomic structures penetrated by each strut. A numeric value was assigned as previously described by Schwartz et al.\textsuperscript{14}: 0 = no injury, 1 = break in the internal elastic membrane, 2 = perforation of the media, and 3 = perforation of the external elastic membrane to the adventitia.

The average injury score for each segment was calculated by dividing the sum of injury scores by the total number of struts at the examined section.

Evaluation of inflammation scores, neointimal reaction, and fibrin score
With regard to the inflammation score for each individual strut, the following grading system was used: 0 = no inflammatory cells surrounding the strut, 1 = light, non-circumferential lymphohistiocytic infiltrate surrounding strut, 2 = localized, moderate to dense cellular aggregate surrounding the strut non-circumferentially, and 3 = circumferential dense lymphohistiocytic cell infiltration of the strut. The inflammation score for each cross section was calculated by dividing the sum of the individual inflammation scores by the total number of struts at the examined section.\textsuperscript{17} Ordinal data for fibrin were collected on each stent section using a scale of 0 to 3, as previously reported.\textsuperscript{18}

Statistical analysis
Statistical analysis was performed with the aid of the commercially available software (SPSS Version 15, Chicago, IL, USA). The data were presented as mean value ± SD. Unpaired Student’s t test was used for the comparison within each stent group. Analysis of variance (ANOVA) was used for comparisons of the three stent groups. Ordinal measurements such as injury score, fibrin score, and inflammation score were analyzed using the Kruskal-Wallis test. Non-parametric results were presented as median and interquartile range. A value of $P<0.05$ was considered statistically significant.

Results
Analysis after stenting
Two stents were placed within two coronary arteries per swine. A total of 36 stents, including 12 THS, 12 ZES, and 12 BMS, were placed in the proximal left anterior descending and proximal circumflex artery for 18 swine. The mortality rate for this study was zero. There was no significant difference in stent-to-artery ratio among the three stent groups.

Histopathologic analysis
There were no significant differences in the injury score (2.0 [range 1.0 to 2.0] in the THS group vs. 2.0 [range 1.0 to 2.0] in the ZES group vs. 2.0 [range 2.0 to 2.0] in the BMS group, $P=NS$) or internal elastic lamina (5.1 ± 0.52 mm\textsuperscript{2} in the THS group vs. 5.1 ± 0.55 mm\textsuperscript{2} in the ZES group vs. 5.0 ± 0.68 mm\textsuperscript{2} in the BMS group, $P=NS$) among the three groups. There were significant differences in neointima area (2.9 ± 0.85 mm\textsuperscript{2} in the THS group vs. 2.8 ± 0.10 mm\textsuperscript{2} in

Fig. 3. Injury score (A), internal elastic lamina (B), lumen area (C), neointima area (D), % area stenosis (E), fibrin score (F), and inflammation score (G) in THS, ZES, and BMS. A, F, and G are expressed as median (red color, interquartile range). THS, TiO\textsubscript{2} film-heparin coated stent; ZES, zotarolimus-eluting stent with biocompatible polymer; BMS, bare metal stent.
Titanium Dioxide Film-Coated Coronary Stent with Heparin

Fig. 4. Scanning electron microscopic results of the stent-implanted coronary arteries. THS implanted (A: 200×), ZES implanted (B: 200×), and BMS implanted (C: 200×).

THS, TiO₂ film-heparin coated stent; ZES, zotarolimus-eluting stent with biocompatible polymer; BMS, bare metal stent.

Fig. 5. Micro-computed tomography (M-CT) of in-stent restenosis (ISR) with THS, ZES, and BMS.

THS, TiO₂ film-heparin coated stent; ZES, zotarolimus-eluting stent with biocompatible polymer; BMS, bare metal stent.
the ZES group vs. 3.3 ± 0.58 mm² in the BMS group, P<0.05), lum
men area (2.1 ± 0.10 mm² in the THS group vs. 2.3 ± 1.14 mm² in
the ZES group vs. 1.7 ± 0.63 mm² in the BMS group, P<0.05), fi
brin score (0.0 [range 0.0 to 1.0] in the THS group vs. 2.0 [range 2.0
to 2.0] in ZES group vs. 0.5 [range 0.0 to 2.0] in the BMS group,
P<0.0001) (Fig. 1), inflammation score (1.0 [range 0.0-1.0] in the
THS group vs. 1.0 [range 1.0 to 2.0] in the ZES group vs. 1.0 [range
0.75 to 1.0] in the BMS group, P<0.0001) (Fig. 2), and percent area
stenosis (57.8 ± 17.34% in the ZES group vs. 55.4 ± 21.22% in the
ZES group 66.2 ± 10.12% in the BMS group, P<0.05) among the
two groups (Fig. 3).

Scanning electron microscopic analysis
SEM revealed complete stent strut coverage in all groups. There was
no significant difference in strut coverage among the three stent
groups (Fig. 4).

Micro computed tomography analysis
The in-stent restenosis rate of M-CT showed similar results with re
spect to percent area stenosis upon histopathologic analysis (57.7 ±
13.14% in the THS group vs. 58.7 ± 16.44% in the ZES group 64.8 ±
8.56% in the BMS group, P<0.05) (Fig. 5).

Discussion
Our study was conducted to compare the THS (TiO₂ film-heparin
coated stent), ZES (zotarolimus-eluting stent with biocompatible
polymer), and BMS (bare metal stent) in a porcine coronary resteno
sis model. Our study showed that THS appeared to offer effective
inhibition of the neointimal proliferation compared to BMS and a
significantly lower fibrin score than the polymer-based ZES.

The cobalt-chromium alloy-based BMS can cause inflammatory
reactions within the stented artery, which lead to neointima prolifera
tion.13 Titanium is commonly used in biocompatible materials for
medical implants, such as those used in dental and orthopedic fields,
because it has excellent mechanical stability and good blood com
patibility. TiO₂ films have better blood compatibility compared to
cobalt-chromium alloy.20 When TiO₂ is coated onto a bare metal
stent, it suppresses inflammation and inhibits blood coagulation.20
Therefore, we coated a TiO₂ thin film onto a cobalt-chromium bare
metal stent via plasma-enhanced chemical vapor deposition. Then,
heparin was grafted onto the modified TiO₂ film-coated stents through
covalent bonding without polymer.13

In our previous study using non-polymeric titanium dioxide film
coated stents with abiciximab (TCA) or alpha lipoic acid (TCALA),
a non-inferior neointima depressive effect was observed compared
to commercial biolimus A9-eluting stent (BES), which used a bio-
absorbable poly-lactic acid and strong immunosuppressive sirolim
us derivatives. Moreover, TCA and TCALA showed significantly
lower inflammation and fibrin scores than BES.22

In vitro study of zotarolimus demonstrated VSMCs and endothe
tial cell proliferation inhibition through binding to FKBP-12. The
zotarolimus-eluting stent significantly reduced neointima hyperpla
sia in a porcine coronary restenosis model.23

In an in vitro study, heparin treatment on proliferating vascular
smooth muscle cells (VSMCs) resulted in decreased ERK pathway
signaling and suppressed VSMCs proliferation. Heparin treatment
causes an elevation of cGMP level, which indicates a role for cGMP-
dependent protein kinase (PKG) in heparin-induced decreased VS
MC proliferation.24

Heparin-coated balloon-expandable Palmaz-Schatz stents reduce
neointima hyperplasia after iliac artery stenting of primates.25 A re
leaseable heparin-coated stent suppressed in-stent neointima prolifera
tion in a porcine coronary restenosis model.26

Delayed arterial healing was defined as fibrin deposition surround
ing the stent strut beyond four weeks after stenting. First-generation
polymer-based DES, such as Cypher and Taxus, showed greater fibrin
score and less re-endothelialization compared with BMS. The persis
tence of fibrin and poor re-endothelialization after stenting were
observed for ST pathologic evaluation. Fibrin deposition sug
gests a potent thrombogenic stimulus.27 Polymers used for coronary
stent coating are associated with vessel wall inflammatory reaction,
restenosis, and late stent thrombosis.

Our result demonstrated that commercial ZES, a polymer-based
drug delivery stent, yielded a greater delay of arterial healing than
non-polymeric THS. Therefore, our developed THS will reduce the
risk of ST compared to polymer-based DES.

This study shows that THS is more effective in reducing neointi
ma formation compared to BMS. Moreover, the neointima suppres
sive effect of THS is superior to commercial polymer-based drug
delivery ZES, with lower fibrin and inflammation scores as measured
one month after stenting in a porcine coronary restenosis model.

Study limitations
Our study had some limitations. First, we used non-atherosclerotic
normal porcine coronary arteries, unlike the likely human clinical
situation with pre-existing atherosclerosis. Second, H&E staining
was used for evaluating inflammatory reaction; immunohistochemi
stry techniques are the standard for such studies.28 Third, long-term
follow-up experiments, greater than six months in duration and us
ing minipigs, were not performed.

Acknowledgments
This work was supported by a grant from the Korean Society on
Thrombosis and Hemosatsis (KSTH 2016-001) and Basic Science
Research Program through the National Research Foundation of
Korea (NRF-2017R1C1B1001956).

Conflicts of interest
The authors declare no conflicts of interest.

References
1. Wenaweser P, Daemen J, Zwahlen M, van Domburg R,
eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study.
J Am Coll Cardiol 2008;52:1134-40.
MC, Schomig A, et al. Outcomes associated with drug-
eluting and bare-metal stents: a collaborative network
3. Murphy JG, Schwartz RS, Edwards WD, Camrud AR,
Vlietstra RE, Holmes DR Jr. Percutaneous polymeric
stents in porcine coronary arteries. Initial experience
with polyethylene terphthlate stents. Circulation 1992;
86:1596-604.
more MH, Alvarez J, et al. Hypersensitivity cases asso
ciated with drug-eluting coronary stents: a review of
available cases from the Research on Adverse Drug
Titanium Dioxide Film-Coated Coronary Stent with Heparin

Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47:175-81.


